Transparent Interactions
Working with Healthcare Professionals and Patients
Strength in collaboration
To develop and deliver innovative treatment of brain disease, we work with a range of stakeholders. These include healthcare professionals, patients and their respective organizations. We collaborate on research, clinical development, exchange of scientific information, and marketing and sales activities.
These interactions are well-regulated by the national laws and industry association regulations that we integrate into our working processes, training and guidance.
We are committed to transparency and our disclosed information follows the current laws or regulations from the industry associations we have joined, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Transfers of value to healthcare professionals and patient organizations
Here you can find an overview, together with the locations, of Lundbeck’s interactions with healthcare professionals and the related transfers of value:
Countries that disclose
Aggregate disclosures
Lundbeck discloses payments and other transfers for value to HCPs and HCOs in aggregate, if the HCP or HCO has used their legal right to refuse consent to individual disclosure, in accordance with the EFPIA Disclosure Code. The data covers Lundbeck affiliates that use Lundbeck’s corporate website for disclosure. Data from other countries can be found on the Country overview tab.
EFPIA aggregate disclosures on this site include data from the following countries and the tables are organized according to EFPIA specifications:
| Event Sponsorships | Consultancies (Fee for Service) | |||
| Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
| Number and % of non-disclosed HCPs | 0 | 4 (3%) | 0 | 0 |
| Amount and % related to non-disclosed HCPs | €0 | €329 (1%) | €0 | €0 |
All Bulgarian HCOs have consented to disclosure.
| Event Sponsorships | Consultancies (Fee for Service) | |||
| Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
| Number and % of non-disclosed HCPs | 0 | 0 | 12 (15%) | 0 |
| Amount and % related to non-disclosed HCPs | €0 | €0 | €4,035.05 (13%) | €0 |
All Croatian HCOs have consented to disclosure.
All Estonian HCPs have consented to disclosure.
All Estonian HCOs have consented to disclosure.
| Event Sponsorships | Consultancies (Fee for Service) | |||
| Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
| Number and % of non-disclosed HCPs | 223 (67%) | 108 (71%) | 0 | 0 |
| Amount and % related to non-disclosed HCPs | €39,900 (76%) | €50,248 (78%) | €0 | €0 |
| Event Sponsorships | Consultancies (Fee for Service) | |||||
| Aggregate HCOs | Donations & Grants |
Sponsorship of HCO | Registration fees | Travel & Accomm. | Fees | Related expenses |
| Number and % of non-disclosed HCOs | 0 | 5 (100%) | 0 | 0 | 7 (78%) | 0 |
| Amount and % related to non-disclosed HCOs | €0 | €5,134 (100%) | €0 | €0 | €40,090 (88%) | €0 |
All Latvian HCPs have consented to disclosure.
All Latvian HCOs have consented to disclosure.
| Event Sponsorships | Consultancies (Fee for Service) | |||
| Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
| Number and % of non-disclosed HCPs | 1 (6%) | 4 (11%) | 0 | 0 |
| Amount and % related to non-disclosed HCPs | €715 (5%) | €2,538 (3%) | €0 | €0 |
All Lithuania HCOs have consented to disclosure.
| Event Sponsorships | Consultancies (Fee for Service) | |||
| Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
| Number and % of non-disclosed HCPs | 7 (58%) | 0 | 7 (20%) | 10 (33%) |
| Amount and % related to non-disclosed HCPs | €3,459 (65%) | €0 | €1,210 (9%) | €16,147 (53%) |
| Event Sponsorships | Consultancies (Fee for Service) | |||||
| Aggregate HCOs | Donations & Grants |
Sponsorship of HCO | Registration fees | Travel & Accomm. | Fees | Related expenses |
| Number and % of non-disclosed HCOs | 2 (100%) | 0 | 0 | 0 | 0 | 0 |
| Amount and % related to non-disclosed HCOs | €30,641 (100%) | €0 | €0 | €0 | €0 | €0 |
Research and development disclosures
Lundbeck undertakes research activities and conducts clinical studies globally. Clinical studies are conducted in accordance with international guidelines and performed by HCPs and HCOs. Our payments and other transfers of value related to pre-clinical, clinical and non-interventional studies are disclosed in aggregate.
| R&D payments to HCPs & HCOs | ||||
| Country | 2015 | 2016 | 2017 | 2018 |
| Bulgaria | €579,823 | €319,234 | €661,840 | €1,349,624 |
| Croatia | 95,822 HRK | 303,693 HRK | €24,431 | €295 |
| Estonia | - | - | €492,586 | €235,171 |
| Hungary | €8,507 | €30,128 | €107,946 | €52,271 |
| Latvia | See country overview | €83,105 | €199,889 | €164,272 |
| Lithuania | €403,371 | €229,952 | €77,033 | - |
| Ukraine | €896,803 | €359,207 | €99,857 | €452,015 |
The amounts cover payments and other transfers of value to HCPs and HCOs related to pre-clinical, clinical and non-interventional studies in the countries where the Lundbeck affiliate uses Lundbeck’s corporate website for disclosure in accordance with the EFPIA Disclosure Code.
Data from other countries can be found under countries that disclose.
More from lundbeck
We pursue our business purpose guided by several pillars and our Code of Conduct.
Our policy for scientific publications and responsible clinical data sharing.
We see patients as people and are committed to support the person behind.